Bright Light Therapy in the Treatment of Non-seasonal Bipolar Depression

Exclusion Criteria

• •Patients under guardianship or deprivation of liberty by administrative or judicial decision
• •Seasonal pattern of major depressive episode according to DSM-5 criteria.
• •Psychotic, mixed, or catatonic characteristics according to DSM-5 criteria
• •High suicidal risk assessed by the Columbia Scale of Suicide Risk Severity (C-SSRS)
• •Not stabilized comorbidities (addictive disorders according to the DSM-5 criteria or other decompensated general medical cause).
• •Ophthalmic pathology (cataract, macular degeneration, glaucoma, retinitis pigmentosa) and diseases affecting the retina (retinopathy, diabetes, herpes, etc.).
• •Photosensitive treatment, including the following treatments:
• •* Cyclins (Vibramycin®, Doxycycline®)
• •* Amiodarone (Cordarone®, Amiodarone®)
• •* Phenothiazines (Largactil®, Modecate®, Nozinan®, Melleril®, Trilafon®)
• •* Methotrexate (Methotrexate®)
• •* Sulfamides (antibiotics, diuretics or hypoglycemic agents)
• •* Chloroquine (Nivaquine®)
• •* Some anti-inflammatories (Apranax®, Indocid®)
• •* Psoralens used in puvatherapy
• •* Isotretinoin (Roaccutane® and generics)
• •* Verteporfin (Visudyne®).
• •Lactating or pregnant women (pregnancy urine positive test).
• •Subjects who have already used light therapy in the last 6 months.
• •Therapeutic resistance of the current major depressive episode (≥2 traditional antidepressants such as SSRI, IRSNA, MAOI or tricyclic, at effective therapeutic dosage for more than 6 weeks)
• •Use of another antidepressant strategy than the mood stabilizer, including antidepressants of all classes (which will have to be stopped before the initiation of light therapy) and psychotherapy with onset \<1 month.